New Medicines for AIDS in Development

.__DEC 19 95 08:28Pi1 PHPR1A
Antivirals

t'.b0" [

DRUG COMPANY INDICATION U.S. DEVELOPMENT STATUS
Retroviret (laxo Weilcome HIV positive (symptomatic) Phase III (M)
zidovudine (AZT) (Rich. Triangle Park, NC)
with VIDEXTM
didanosine (ddl)
ritonavir Abbott Laboratories unspecified Phasc III (WCMA)
(Abbott Park, IL)
T301 77, AR-177 Aronex Pharmaceuticals AIDS Phas I (WMA)
oli cnucleotide (The Woodlands, TX)
TI-23 Teijin America CMV retinitis Phase I (MAB)
(New York, NY)
Teijin Ltd.
(Tokyo apan)
Tucaresol Glaxo Wellcome HIV infection Phase I/11
irmunnopotenriator (Rsch. Trianglc Park, NC)
Valtrexrmt Glaxo Welicome treatment of genital herpes application (M)
valacyciovir (Rsch. Triangle Park, NC) simplex virus (H-SV) submitted
N"- w"w.-efM1-N~ i" " ~sNr.""s r"." N"" suppression of genital herpes Phase III (M)
simplex virus (HSV)
suppression of CMV infection Phasc III (WMA)
and disease
-mmVIDEXt Bristol-Myers Squibb HIV infection in clinical trials
didanosinc (ddl) (Princeton, NJ)
with Retrovir
zidovudine (AZT)
VIDEX t Bristol-Myers Squibb HIV infection in clinical trials
didanosine (dd (Princeton, NJ)
with ZeritlM
stavudine (d4T)
VIMIRxyn'h VIMRx Pharmaceuticals HW, AIDS Phase I (WMA)
h ypricin (Stamford, CT)
Viraceptn'h Agouron Pharmaceuticals IV infection Phase H1 (WMAB)
AG01343 (Lsa Jolla, CA)
Virarnme Boehringer ingelbeim management of HIV infection Phase 1I/lU1 (WCMAB)
nevirapine Pharmaceuticals in combination with VIDEX and
(Ridgefield, CT) Rerrovit' in previously treated
patients for whom current therapy
is deemed inadc uace
Virerad Shaman Pharmaceuticals genital herpes Phase II
SP-303 (S. San Francisco, CA)
Vistidem Gilcad Sciences CMV retinj js in AIDS patients application (WMA)
cidofovir (IV) (Foster City, CA) submnitted
VX-4d78 Vertex Phrmaceuti clTHV infectrin.AIDSPaseI (WA)